The Asia-Pacific healthcare CDMO market is projected to grow at a significant CAGR during the forecast period. The significant growth in the pharmaceutical contract manufacturing industry in China, India, and Japan further provides ample opportunity to the market. The pharmaceutical contract manufacturing firms are also focusing on expanding their business operations.
For example, in 2017, Fujifilm Holdings plans to widen its biopharmaceutical contract manufacturing business. The company is expanding the capacity of its culture tanks by the year 2019 and plans to hire more engineers for proper management of its manufacturing operations. This enables the company to offer much efficient manufacturing services to the pharmaceutical industry.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-healthcare-cdmo-market
Moreover, the Asia-Pacific regenerative medicine industry is also expected to grow in near future due to ease in regulations, supporting to drive the biotech industry in Asia-Pacific. For example, in 2014, the Japanese government passed the PMD (Pharmaceutical and Medical Device Act). Under the act, a product related to new cell therapy can be tentatively approved by the regulatory authorities as its safety and effectiveness have been established. This act supports regenerative medicine companies to shorten the time lag between the product development and market introduction of new products.
The effect of the PMD act has been shown in the Life Science World 2016 that attracted a large number of companies specializing in experiment equipment, cell culture materials companies. Moreover, it also attracts a large number of cell CMO firms. This exhibition signifies the positive vision of the regenerative medicine industry in the region that further spurs the healthcare CDMO market in the region.
Key questions addressed by the report
- What is the market growth rate during the forecast period?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market during the forecast period?
- How COVID-19 will impact the market growth in 2020 and the coming years?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
o Recommendations
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific healthcare CDMO Market – Segmentation
By Services
- Contract Development
o Clinical
o Preclinical
o Laboratory Services
- Contract Manufacturing
o Active Pharmaceutical Ingredients( API)
o Finish Dosage Formulations
o Medical Devices
A full report of Asia-Pacific Healthcare CDMO Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-healthcare-cdmo-market
Asia-Pacific Healthcare CDMO Market– Segment by Region
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Company Profiles
- AbbVie Inc.
- Almac Group Ltd.
- Baxter International, Inc.
- Braun Melsungen AG
- Boehringer Ingelheim International GmbH
- Catalent Inc.
- Covance Inc.
- Lonza Group Ltd.
- Pfizer Inc.
- Thermo Fisher Scientific Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research